Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 8/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18148040 | 0.84 | CNKSR1 (0.57) | CNKSR1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL18148043 | 0.84 | CNKSR1 (0.57) | CNKSR1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL18148089 | 0.74 | CNKSR1 (0.53) | CNKSR1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL18148085 | 0.74 | CNKSR1 (0.53) | CNKSR1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL18148195 | 0.73 | CNKSR1 (0.56) | CNKSR1POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL18148198 | 0.73 | CNKSR1 (0.56) | CNKSR1POLBKDM4EALDH1A1MEN1 | |
| SCHEMBL18163743 | 0.70 | CNKSR1 (1.00) | CNKSR1ALDH1A1 | |
| SCHEMBL18163745 | 0.68 | CNKSR1 (0.79) | CNKSR1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL18163747 | 0.66 | CNKSR1 (0.82) | CNKSR1ALDH1A1 | |
| SCHEMBL18163741 | 0.66 | CNKSR1 (1.00) | CNKSR1ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885CYP1A1 4305/4885CYP1B1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.